Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
about
A novel computational biostatistics approach implies impaired dephosphorylation of growth factor receptors as associated with severity of autism.A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disordersTreatment of neurodevelopmental disorders in adulthoodTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesPreventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia.Abnormalities in the zinc-metalloprotease-BDNF axis may contribute to megalencephaly and cortical hyperconnectivity in young autism spectrum disorder patients.Two classes of matrix metalloproteinases reciprocally regulate synaptogenesis.Effects of minocycline on spatial learning, hippocampal neurogenesis and microglia in aged and adult mice.Biotic acts of antibioticsFragile X mental retardation protein regulates trans-synaptic signaling in DrosophilaNew innovations: therapeutic opportunities for intellectual disabilities.Using genetic findings in autism for the development of new pharmaceutical compounds.MMP-9 in translation: from molecule to brain physiology, pathology, and therapy.The quest for fragile X biomarkers.Multifarious Functions of the Fragile X Mental Retardation Protein.Looking Inside the Matrix: Perineuronal Nets in Plasticity, Maladaptive Plasticity and Neurological Disorders.A Drosophila model of Fragile X syndrome exhibits defects in phagocytosis by innate immune cells.Minocycline attenuates cardiac dysfunction in tumor-burdened mice.Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.Secreted tissue inhibitor of matrix metalloproteinase restricts trans-synaptic signaling to coordinate synaptogenesis.Minocycline improves peripheral and autonomic neuropathy in type 2 diabetes: MIND study.Paradoxical effects of minocycline in the developing mouse somatosensory cortex.Neutrophil Infiltration and Matrix Metalloproteinase-9 in Lacunar Infarction.Microglia and Autism Spectrum Disorder: Overview of Current Evidence and Novel Immunomodulatory Treatment Options
P2860
Q24612710-763976CC-DEB0-4A1C-B990-6598D365910AQ26797397-255AE1CA-1277-4B64-A597-8AC26265D80BQ27000307-12B0D28E-C16D-45B7-B126-0D946342B17DQ27023257-E019E448-457B-4562-A326-F02DEF236CF0Q30383068-6F3A4408-258E-49C4-9DEC-FDB4D932038CQ34545273-C4E4703D-4564-41DA-89FF-5EA17E088656Q36497245-03743C1F-8412-49F2-BFD1-18138FECA633Q37051935-4DB05F81-F90D-4133-A72A-1CD17E2ED10FQ37101851-BC75805B-8CAF-429F-A030-BFC31F7C870CQ37287441-120036C3-E46B-44E1-BBF0-FFD163D5BAB6Q38137883-C8068F13-8A39-4F0A-ACB7-7DBA86A99CC9Q38167615-D576D7C9-DDCC-4A2C-9C3D-5D74CB71B2CDQ38622769-97805866-8B35-416D-A90F-88DB15214839Q38633043-88308859-4662-4E59-B3B1-F1D9530EC3C6Q38639448-6A0EE606-1C3E-4075-9FB7-2F3382573656Q38758334-14D678E3-50D6-481E-8F2C-2BD97DE57A88Q40323144-558A5E25-EBE3-4C32-A481-C66F2A946D41Q42860182-FCE86389-5212-43C4-BA46-8590E9FC3903Q42927941-728C61BA-9E34-4E81-92A3-3DC4DC9C9A21Q48333842-5BB57B65-DB46-4CBD-A6A1-3B4D056DF029Q48357574-45E0AABA-2148-49CE-8DC6-0802A96B1503Q50465997-82A8D42C-A0D1-4462-A2EA-3A54F48DC0DDQ52680681-17FAB963-A3C6-437B-9532-6EFC24B615BCQ58781425-82D32C57-A702-4772-85F8-B0B81233387D
P2860
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome
@nl
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
@ast
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
@en
type
label
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome
@nl
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
@ast
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
@en
prefLabel
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome
@nl
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
@ast
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
@en
P2860
P921
P3181
P356
P1433
P1476
Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.
@en
P2093
Kendal Broadie
Saul S Siller
P2860
P304
P3181
P356
10.1155/2012/124548
P407
P5008
P577
2012-05-20T00:00:00Z